## **Journal of Visualized Experiments**

# Capturing small molecule communication between tissues and cells using imaging mass spectrometry --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video		
Manuscript Number:	JoVE59490R2		
Full Title:	Capturing small molecule communication between tissues and cells using imaging mass spectrometry		
Keywords:	Imaging Mass Spectrometry; ovarian cancer; 3D cell culture; coculture; tissue; Cells; metabolomics		
Corresponding Author:	Laura Sanchez University of Illinois at Chicago Chicago, IL UNITED STATES		
Corresponding Author's Institution:	University of Illinois at Chicago		
Corresponding Author E-Mail:	sanchelm@uic.edu		
Order of Authors:	Katherine E Zink		
	Matthew Dean		
	Joanna E Burdette		
	Laura Sanchez		
Additional Information:			
Question	Response		
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)		
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Chicago, Illinois, USA		



Medicinal Chemistry and Pharmacognosy (MC 781) College of Pharmacy 833 South Wood Street Chicago, Illinois 60612-7229

December 4, 2018

**RE: JOVE Invited Article Submission** 

Dear Dr Weldon,

Many cancers metastasize to specific tissues and we believe the underlying cause of tissue/organ specific metastasis likely revolves are chemical signaling cues. We have recently published a new imaging mass spectrometry (IMS) technique to accomplish this task. IMS has historically been used with tissues, 3D cell cultures (spheroids) and microbial colonies. Specifically, in microbes, agar based IMS studies have facilitated exciting discoveries in the microbiology and natural products fields (Yang et al. 2009, Nat Chem Biol) since it was reported by the Dorrestein lab in 2009. We believe our methodology will open new avenues to studying the chemical exchange between cells and tissues in cancer research in the same way microbial imaging mass spectrometry has for microbiology. We are hopeful that this would excite the readership of JOVE as it represents an innovative approach to studying the chemistry related to cancer progression.

Below is a list of knowledgeable referees that could evaluate this paper. They have been chosen based on their expertise in imaging mass spectrometry, ovarian cancer, and methodology development.

Amanda Hummon, The Ohio State University; hummon.1@osu.edu Expertise: Mass spectrometry imaging, discovery of metabolite and protein based biomarkers using mass spectrometry in cancers

David Muddiman, North Carolina State University; dcmuddim@ncsu.edu Expertise: Mass spectrometry imaging instrument and method development, ovarian cancer in unusual model systems

Ernst Lengyel, University of Chicago; elengyel@uchicago.edu Expertise: Diagnosis and treatment of gynecologic malignancies, specifically, ovarian, cervical and endometrial cancers

Thank you in advance for considering this manuscript. Sincerely,

Laura Sanchez, PhD Assistant Professor

University of Illinois at Chicago

833 S Wood St, MC 781

LawSur



Chicago, IL 60612 Phone: (312) 996-0842 Email: sanchelm@uic.edu

Website: http://www.sanchezlab.science/



2 TITLE:

3 Capturing Small Molecule Communication Between Tissues and Cells Using Imaging Mass 4 Spectrometry

5 6

1

#### **AUTHORS AND AFFILIATIONS:**

- 7 Katherine E Zink<sup>1</sup>, Matthew Dean<sup>1,2</sup>, Joanna E Burdette<sup>1</sup>, Laura M Sanchez<sup>1</sup>
- 8 <sup>1</sup>Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago,
- 9 Chicago IL, 60612
- <sup>2</sup>Department of Animal Science. University of Illinois at Urbana-Champaign, Urbana, IL, United
- 11 States.

12 13

#### **Corresponding Author:**

- 14 Laura M Sanchez (sanchelm@uic.edu)
- 15 Tel: (312) 996-0842

16 17

#### **Email Addresses of Co-authors:**

- 18 Katherine Zink (kzink2@uic.edu)
- 19 Matthew Dean (mjdean@illinois.edu)
- 20 Joanna Burdette (joannab@uic.edu)

2122

#### **KEYWORDS:**

imaging mass spectrometry, ovarian cancer, 3D cell culture, coculture, tissue, cells, metabolomics

2425

23

#### **SUMMARY:**

A novel method of sample preparation was developed to accommodate cell and tissue coculture to detect small molecule exchange using imaging mass spectrometry.

272829

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

26

#### **ABSTRACT:**

Imaging mass spectrometry (IMS) has routinely been applied to three types of samples: tissue sections, spheroids, and microbial colonies. These sample types have been analyzed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to visualize the distribution of proteins, lipids, and metabolites across the biological sample of interest. We have developed a novel sample preparation method that combines the strengths of the three previous applications to address an underexplored approach for identifying chemical communication in cancer, by seeding mammalian cell cultures into agarose in coculture with healthy tissues followed by desiccation of the sample. Mammalian tissue and cells are cocultured in close proximity allowing chemical communication via diffusion between the tissue and cells. At specific time points, the agarose-based sample is dried in the same manner as microbial colonies prepared for IMS analysis. Our method was developed to model the communication between high grade serous ovarian cancer derived from the fallopian tube as it interacts with the ovary during metastasis. Optimization of the sample preparation resulted in the identification of norepinephrine as a key chemical component in the ovarian microenvironment. This newly developed method can be applied to other biological systems that require an understanding of

chemical communication between adjacent cells or tissues.

## INTRODUCTION:

Imaging mass spectrometry (IMS) has been optimized to characterize the spatial distribution of molecular features in three widely used applications: tissue slices, spheroids, and microbial colonies<sup>1-3</sup>. Tissue slices can be used to evaluate the localization of metabolites in the context of biological conditions in a host, either targeted or untargeted within a specific mass range. However, differences between molecular features are the most significant and obvious when a healthy tissue is compared to a diseased condition, for example, a tumor. This IMS approach is particularly adapted to detection of disease biomarkers, however, acquiring tissue samples at discrete stages in disease progression (such as tumor grades) precludes the identification of signals that could be important for initiation of the disease. The exchange of information through space is a ubiquitous feature of many biological systems, and tissue slices cannot capture this dynamic chemical relay. One technique that is capable of visualizing chemical exchange and diffusion is IMS of microbial colonies grown on agar plates; small molecules are able to diffuse through and across the agar and can be captured via matrix-assisted laser desorption/ionization (MALDI-TOF) mass spectrometry<sup>4</sup>. This growth setup can be used to identify molecules exchanged between discrete biological entities (colonies) and can also determine directionality of metabolite production. The platform originally designed for microbial colony growth was adapted to explore the primary metabolism of tissue explants grown with mammalian cells, and IMS was used to evaluate the dynamic chemical exchange in an in vitro mammalian system.

In the past several years, it has become clear that high grade serous ovarian cancer (HGSOC) often originates in the fallopian tube epithelium (FTE) and then metastasizes to the ovary during early disease development<sup>5–8</sup>. The reason that tumorigenic FTE cells spread to the ovary, where large tumors eventually form and metastasize further, is currently unclear. Previous research has focused on the role of ovarian proteins in primary metastasis to the ovary; however, it has recently been demonstrated that the transition from a healthy to a tumorigenic tissue results in massive disruption of cellular metabolism and alters production of small molecules<sup>9–11</sup>. Therefore, we hypothesized that small molecules exchanged between the FTE and the ovary may be partly responsible for primary metastasis of HGSOC.

Using our newly developed IMS procedure, we have determined that coculture of tumorigenic FTE and healthy ovarian tissue induces the production of norepinephrine from the ovary. However, other cell types or normal FTE cells did not elicit this effect. An extraordinary benefit of this method is that the molecular production and exchange of signals that represent real molecules can be visualized, so even in a coculture it is possible to determine the source of a signal. This is an advantage over analysis of homogenized samples, where all spatial information is lost. In our model system, we were able to clearly assign the production of norepinephrine to the ovary. Norepinephrine has been linked to the metastasis and chemoresistance of ovarian cancers, and our detection of this molecule has validated that the novel IMS method can uncover biologically relevant molecules<sup>12–14</sup>. This validation lets us propose that this new application of IMS can be particularly helpful to research groups that are attempting to identify small molecules in coculture environments and to understand early events that influence cell transformation and

metastasis. The overall goal of this method is to elucidate the identity and spatial distribution of small molecules during exchange between tissues and organs, represented either by in vitro 3D cell cultures or ex vivo tissue.

91 92 93

89

90

#### PROTOCOL:

94 95

96

97

All animal procedures were in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and approved by the Institutional Animal Use and Care (IACUC) committee at the University of Illinois at Chicago.

98 99

#### 1. Preparation of reagents

100

- 1.1. Maintain MOE cells at 37°C with 5% CO<sub>2</sub> in a humidified incubator in alpha Minimum
  102 Essential Medium (αMEM) media supplemented with 10% fetal bovine serum (FBS), 2 mM L-
- 102 Essential Medium (αMEM) media supplemented with 10% fetal bovine serum (FBS), 2 mM L-103 glutamine, 10 mg/mL insulin, transferrin, selenium (ITS), 1.8 ng/mL epidermal growth factor
- 104 /ECE) 100 H/ml popicillin stroptomysin 1 mg/ml goptomysin and 10.2 ng/ml ostradiol 170
- 104 (EGF), 100 U/mL penicillin-streptomycin, 1 mg/mL gentamycin, and 18.2 ng/mL estradiol-17β.
- Pass the cells every 3–4 days, ensuring there are enough cells on the same day the mice will be sacrificed.

107

- 108 1.2. Prepare 2% agarose by mixing 1 g of low-melting agarose with 50 mL of distilled water.
- 109 Autoclave the agarose, allow to cool, and then aliquot (1 mL) in 2-mL tubes (see Table of
- 110 Materials) before agarose solidifies. Agarose can be stored at -20 °C indefinitely.

111

1.3. Prepare at least 2 mL of 1x Dulbecco's Modified Eagle's Medium (DMEM) media.

113

- 1.4. For the matrix for MALDI-TOF MS, prepare 10 mL of 5 mg/mL 1:1 alpha-cyano-4hyroxycinnamic acid (CHCA):dihydroxybenzoic acid (DHB) (see **Table of Materials**) in 90:10
- 116 ACN:H<sub>2</sub>O + 0.1% trifluoroacetic acid (TFA). Sonicate solution until matrix is dissolved.

117

118 2. Mouse colony and ovary removal

119

2.1. Maintain breeding pairs of CD-1 mice using standard housing procedures. Near the day of parturition, check the mice every day so that the age of the pups is known.

122

- 123 2.2. Euthanize pups at 16-18 days of age by  $CO_2$  inhalation per NIH guidelines. Deliver  $CO_2$  (100%)
- at a flow rate of 10%–20% chamber volume per minute and continue for two minutes after
- respiration had stopped. Confirm euthanasia by cervical dislocation.

126

2.3. Disinfect all surgical equipment by submerging in 70% ethanol. Warm Leibovitz's L-15 media
 with 1x penicillin-streptomycin to 37°C.

- 130 2.4. Wet the abdominal surface with 70% ethanol to disinfect the area and minimize
- contamination with hair. Grasp the skin covering the abdominal wall using blunt forceps and use
- surgical scissors to make a large V-shape cut through the skin and abdominal wall, exposing the

133 guts.

2.5. Move the guts to the side using forceps. Individually grab each uterine horn with fine forcepsand lift slightly.

2.6. Locate the ovary, which will be at the end of the uterine horn, immediately below the kidney.
 Use surgical scissors to dissect the ovary free of connective tissue. Then, cut the ovarian horn in half.

2.7. Move the ovary, oviduct, and approximately one half of each uterine horn to pre-warmed
 Leibovitz's L-15 media.

2.8. Under a dissecting microscope carefully move each ovary from the surrounding bursa, freeing it from the oviduct, bursa, and any adipose tissue. Move each ovary to a new dish of Leibovitz's L-15 media.

2.9. Cut each ovary in half axially. Keep the ovarian pieces (now called explants) kept at 37 °C until plating of agarose.

3. Setting up and incubating the ITO-treated slide for cocultures

3.1. Undivided cocultures

3.1.1. Liquify the agarose at 70 °C on a hot plate.

3.1.2. Place the 8-well divider on top of the indium tinoxide (ITO)-treated slide (**Figure 1A**). The rubber bottom on the divider aids in adhesion to the slide, but make sure to apply continuous gentle downward pressure during agarose plating to ensure no leaking or mixing between wells.

3.1.3. Collect cells in a 15 mL conical tube, centrifuge (5 min at 800 rpm), and resuspend to 50k cells per 150  $\mu$ L in 1x DMEM media. If a different cell density is optimal, make sure that at this step the cell suspension is 2x the final density desired (e.g., for a final concentration of 50,000 cells in 300  $\mu$ L, cell density at this step is 50,000 cells in 150  $\mu$ L).

3.1.4. Before plating cell culture, add ovarian explant to center of well (Figure 1B).

3.1.5. Add agarose to each cell culture in individual 2-mL tubes just before plating. For each well, combine 200  $\mu$ L of cell suspension and 200  $\mu$ L of liquified agarose in a 2-mL tube. For example, for four wells, combine 800  $\mu$ L of cell suspension and 800  $\mu$ L of 2% agarose. Some mixture will be left over, but making slightly more than necessary avoids air bubbles during pipetting.

3.1.5.1. Add agarose to individual cell cultures immediately before plating that cell culture. The agarose will cool in under a minute, so be prepared to plate quickly.

3.1.6. Immediately add 300 μL of the cell/agarose mixture to each well (**Figure 1C**). **Figure 1C** shows three cell conditions and one media condition, each plated with and without an ovary.

3.1.7. Incubate slide at 37 °C and 5% CO₂ in a humidified incubator.

182 3.2. Divided Cocultures.

3.2.1. Cut dividers from thin, smooth plastic (Figure 2A).

NOTE: This experiment uses the sides of a sterile disposable media basin because they are flat and thin. Cut them just wide enough to fit snugly into the hypotenuse of the well (~13 mm).

189 3.2.2. Liquify the agarose at 70 °C on a hot plate.

3.2.3. Place the 8-well divider on top of the ITO-treated slide (**Figure 2B**). The rubber bottom on the divider aids in adhesion to the slide, but make sure to apply continuous gentle downward pressure during agarose plating to ensure no leaking or mixing between wells.

3.2.4. Collect cells in a 15 mL conical tube, centrifuge (5 min at 800 rpm), and resuspend to 50k cells per 150  $\mu$ L in 1X DMEM media. If a different cell density is optimal, make sure that at this step the cell suspension is 2X the final density desired (e.g. for a final concentration of 50,000 cells in 300  $\mu$ L, cell density at this step is 50,000 cells in 150  $\mu$ L).

3.2.5. Insert plastic dividers diagonally into wells (Figure 2C).

3.2.6. Add agarose to each cell suspension one at a time just before plating. For each well, combine 100  $\mu$ L of cell suspension and 100  $\mu$ L of liquified agarose in a 2-mL tube. For example, for four wells, combine 400  $\mu$ L of cell culture and 400  $\mu$ L of 2% agarose. Some cell/agarose mixture will be left over but making slightly more than necessary avoids air bubbles during pipetting.

208 3.2.6.1. Add agarose to individual cell cultures immediately before plating that cell culture. The agarose will cool in under a minute, so be prepared to plate quickly.

3.2.7. On one side of the divider, plate 150 μL of cell/agarose mixture. Allow agarose to cool and
 solidify (approximately one min) and then remove the divider (Figure 2D).

3.2.8. Place ovary explant in the center of the empty half of the well. Place 150 μL media/agarose
 mixture over top of the ovary, and only in the correct side of the well (Figure 2E).

3.2.9. Incubate slide at 37 °C and 5% CO₂ in a humidified incubator.

4. Drying slide and preparing for MALDI-TOF MS.

- 4.1. After four days (or any preferred time point), remove the chamber divider from the agarose plugs and the slide (**Figure 1D**). Gently detach the sides of the agarose from the chamber with a flat spatula and gently pull the chamber upward, being careful not to move any agarose plugs. If they do move, gently reposition them so that they are not touching one another.
- 225
  226
  4.2. Place the slide in a 37 °C oven for approximately 4 h, rotating 90° every h.
- NOTE: The rotation of the slide is important to ensure even heat distribution throughout the sample.
- 4.3. Once dry, remove the slide from the oven (**Figure 1E**).

227

230

232

236

241242

243

244

245

246

249

251

254

257

260

- 4.4. Apply matrix solution using the sprayer (**Figure 1F**), with the following parameters: temperature = 30°C, flow rate = 0.2 mL/min, number of passes = 8, direction = CC, and nozzle distance = 40 mm.
- NOTE: In lieu of a matrix sprayer, an artistic airbrush can be used to apply liquid matrix. The same matrix solution can be used to spray, but approximately twice as much solution is required. With the slide clamped so that it hangs vertically, spray the slide from a 90° angle from approximately one foot away (see Hoffmann<sup>15</sup>) until the matrix layer is visible.
  - 4.5. Add 1  $\mu$ L of calibrant (Phosphorus Red for targets <500 Da, a peptide mixture (see **Table of Materials**) for targets <5000 Da) to clear spot on slide. Phosphorus Red requires no mixing with matrix, but the peptide mixture requires 1:1 mixture with matrix to aid ionization. Wait for calibrant to dry.
- 247 4.6. Draw an X using a permanent marker in each corner of the slide and take an optical image using a camera or a scanner at 1200 dpi.
- 250 5. Imaging mass spectrometry data acquisition
- 5.1. Open a new sequence on the IMS data analysis software (see **Table of Materials**). Set the raster width to desired spatial resolution, at least 50 μm.
- 5.2. Upload the optical image of the slide to the analysis software and set three teach points using the intersections in the X's drawn in each corner.
- 5.3. Designate regions of interest for imaging in the acquisition software and name them accordingly.
- 5.4. Calibrate the instrument using the data acquisition software (see **Table of Materials**) within
   5 ppm error.
- 264 5.5. Save the optimized method and begin run. This experiment optimized the following

parameters: Polarity = Positive, Detector = Reflectron, Laser size = 2, Laser power = 50%, Reflector mode detector gain = 3x.

#### 6. Processing IMS data

6.1. Import .mis file into statistical software (see **Table of Materials**) for analysis of significance.

#### **REPRESENTATIVE RESULTS:**

An optimal dried ITO slide will result in a flat desiccated sample with minimal to no wrinkles across the surface of the agarose and agarose pieces that maintain spatial separation on the slide (Figure 3). Figure 3A shows optimal drying, while Figure 3B shows the wrinkles that should be avoided. This optimization requires careful monitoring of the slide in the oven, as exact times can vary based on the relative humidity. While wrinkles can slightly affect the height, and therefore the mass accuracy of the IMS signals, slight wrinkles will not impact the quality of the data. Therefore, any agarose that ultimately has slight wrinkles can still be analyzed via MALDI-TOF MS. The slide must be completely dried or this could lead to an explosion of the sample in the high vacuum environment of the MALDI-TOF mass spectrometer.

Other substrates aside from agarose may work, but often times do not maintain their structural integrity upon drying or removal of the well chamber, which results in spreading across the ITO slide and loss of spatial information. For example, we have previously tested collagen as a substrate and this resulted in spreading and loss of spatial information when the well chamber was removed (data not shown). The tissue used should be in the center of the well if it is undivided, or in the center of the half triangle if it is divided, so that acquisition of IMS data is not contaminated with edge effects. **Figure 4** shows examples of optimally located tissue (panel A) and badly positioned tissue (panel B). In **Figure 4B**, the tissue is located on the edge of the agarose which, when imaged, may result is false mass signals from the edge effects, and does not allow users to image the agarose surrounding the tissue, which means that secreted signals may be missed during analysis. Tissue should be as close to the center as possible, as demonstrated in **Figure 4A**.

A series of experiments determined that an 8-well chamber was the best vessel for incubation, as compared to a 6-well plate and a 24-well plate, because the 8-well chamber results in minimal perturbations to the cells, whereas the other larger chambers require agarose slabs to be transferred to an ITO or stainless steel slide following incubation<sup>16</sup>. The 8-well chambers from several brands of chamber slides can be used, but those with an adhesive rubber bottom and parallel sides of the wells facilitate easy introduction and removal of a plastic divider for the divided wells. The 6-well plate required much more material and faced difficulties with drying such large areas. The 24-well chamber also had problems during drying, because the meniscus effect was evident in the wells and therefore, the plugs dried with significantly higher edges. The 8-well chamber does not result in the meniscus effect when the agarose is plated directly in the center of the well, and agarose plugs do not have to be transferred. Additionally, the 8-well chamber allows for 8 conditions to be tested or controlled for in a single experiment. Depending on the experiment, it may be important to include controls such as (1) wells with no ovarian

explants or cells, (2) wells with cells only, or (3) wells with ovarian explants only. Because the sample preparation (precise media and agarose concentration, matrix amount, etc.) differs slightly between runs, conditions should be compared when they are acquired on the same slide.

Further experiments determined that an ITO-coated slide was the best platform for incubation when compared to a steel MALDI plate because the slide allows for visual verification of the cell state and positioning. For instance, using the ITO slide, we can verify that the cells have normal morphology and that they maintain homogenous distribution throughout the agarose prior to and following desiccation<sup>16</sup>. The slide will also allow for incorporation of fluorescent cell lines as needed. Additionally, removal of the chamber prior to desiccation is required to maintain the entirety of the agarose plug. If the slide is desiccated with the 8-well chamber adhered, the plastic pulls the agarose plug apart and results in major cracks in the plugs. **Figure 5** demonstrates the problems faced when the chamber is not removed prior to drying.

When analyzing cell populations, it is important the that spatial resolution is at least 50  $\mu$ m. With sprayed matrix, it is possible to do 5  $\mu$ m resolution, but this lengthens the overall time to gather the mass spectrometry data while yielding comparable results. Spatial resolution is also dependent on the ability to focus the laser in the MALDI-TOF mass spectrometer.

Overall, we have optimized this slide setup to best detect exchanged small molecules in coculture. Therefore, during data analysis we are seeking molecular features that are only present or are significantly more abundant in an agarose plug that represents the biological condition of interest. Because there is the option to include seven other controls and conditions on the slide, this can be achieved visually and by the aid of statistical software designed for IMS data. Our dereplication process following the detection of spatially relevant masses is extensive so that we can orthogonally obtain a high-resolution mass and fragmentation data. The first step that we take for dereplication is a search of the nominal mass through a database, such as the Human Metabolome Database (HMDB) for mammalian metabolites. Most of the molecules in the database have a significant number of spectra covering many techniques for comparison to experimental data. Once nominal masses have potential candidate molecules as their putative identity, it is often possible to compare physical data such as MS/MS fragmentation, UV profile, and retention time between the candidate structure and a standard.

For example, identification of norepinephrine in the coculture of tumorigenic FTE cells incubated with ovarian tissue has validated that this IMS method is capable of detecting relevant small molecules from this system<sup>16</sup>. **Figure 6** depicts the sensitivity of the IMS runs, showing the type of data one may expect by following the protocol for undivided chambers. **Figure 7** similarly shows representative data for the divided chamber setup.

#### **FIGURE AND TABLE LEGENDS:**

Figure 1: Workflow for sample preparation of undivided coculture. (A) Adhere 8-well chamber to conductive side of ITO-coated slide. (B) Place halved ovaries in center of wells for coculture conditions. (C) Add 300  $\mu$ L of agarose/cell suspension directly into wells. Make sure there are no

air bubbles and that the ovary remains in the center of the well. If the pipetted agarose disturbed the ovary, gently use the pipet tip to center it before the agarose cools. (**D**) After four days of incubation (or otherwise optimized time) remove 8-well chamber from slide. If agarose remains attached to chamber, gently detach agarose plug from chamber using a spatula and reposition it on the slide. The agarose will not adhere to the slide, so it will be easy to move. Draw an 'X' on each corner of the slide and take a photo. (**E**) Dry the slide in a 37 °C oven for 4 h, rotating 90° each hour. Agarose should be fully desiccated and should lie flat on the slide. (**F**) Apply matrix of choice via a sprayer or airbrush to slide. Matrix layer should be visible as yellow. Scan the slide on a scanner at 1200 dpi and add calibrants or standards for MALDI-TOF MS analysis.

Figure 2: Workflow for sample preparation of divided coculture. (A) Cut tabs out of media basin (~13 mm) and ensure that sides are straight. (B) Attach 8-well chamber to conductive side of ITO-coated slide. (C) Insert dividers diagonally into wells. (D) Add 150  $\mu$ L cell culture in agarose to one side of divider, allow agarose to cool, and remove divider. (E) Add ovary to center of empty well half and cover with 150  $\mu$ L of media and agarose suspension. This figure reproduced with permission from Zink et al. 2018<sup>16</sup>.

**Figure 3: Wrinkles in agarose plugs.** Wrinkles can form in the agarose plugs if the slide is left in the oven for too long. This will not preclude the sample from MALDI-TOF MS analysis but may affect the quality of data. (**A**) Image of an optimally dried slide. All of the agarose surrounding the ovarian tissue is completely flat and free of wrinkles, providing ample area for IMS analysis. (**B**) Image of a poorly dried slide with wrinkled agarose throughout the sample. This figure reproduced with permission from Zink et al. 2018<sup>16</sup>.

**Figure 4: Positioning of tissue.** Position of tissue in dried sample is very important for data acquisition. (**A**) Dried agarose plugs of divided chambers show the ovary in the center of one half of the well, which is optimal for imaging. (**B**) Dried agarose plugs of divided chamber where ovary was not centered for incubation or drying. The ovarian tissue dried on the perimeter of the agarose plugs, and therefore cannot be analyzed.

**Figure 5: Drying slides with the chamber.** When the slide is set in the oven prior to chamber removal, the agarose plugs adhere more strongly to the plastic than to themselves and begin to pull apart in the heat. This results in severe cracks in the agarose, and little adhesion to the slide itself. Cracks this large are not conducive to IMS analysis. Top: Slide after 2 h desiccation with 8-well chamber adhered. All agarose plugs but two cracked through the center due to adhesion to the 8-well chamber. Bottom: Slide after removal of 8-well chamber. Only one agarose plug remained on the slide. This figure reproduced with permission from Zink et al. 2018<sup>16</sup>.

**Figure 6: Detecting unique signals.** When comparing 8 conditions, it is possible to detect signals that are unique to one single condition. (**A**) The dried slide image is used to teach the MALDI-TOF mass spectrometer which regions to image. Here we have selected small regions around the ovarian tissue for IMS at 50  $\mu$ m. (**B**) A representative image of a m/z signal that is upregulated in one condition versus all eight on the same slide.

Figure 7: Representative data from divided chamber setup. Ovarian tissue is outlined in white. The m/z 112 is secreted from the half of the well containing the ovary. IMS was performed at 50  $\mu$ m. This figure reproduced with permission from Zink et al. 2018<sup>16</sup>.

## DISCUSSION:

There is a growing body of evidence that implicates norepinephrine's role in HGSOC<sup>12,17,18</sup>, and this technique has contributed more mechanistic information. With at least eight biological conditions present on the same slide, the method can account for biological controls such as gene and cell specificity as well as media controls in a single IMS run. While the method was optimized to evaluate exchanged small molecules in primary metastasis in HGSOC, any cell or tissue type that can be placed in agarose can be substituted to analyze a wide variety of biological questions and disease states.

One of the most important steps in the protocol is ensuring that the tissue or cell types are in close proximity to one another and are present in the center of the agarose plug. Another important consideration is optimization of the drying time for the entire slide. This method was optimized using ovarian tissue, which dried easily and whose small size resulted in little drying complications. However, other tissues, with different composition such as fat, have very different drying profiles and therefore require more extensive desiccation optimization. After drying has been optimized for the biological sample, the remaining workflow should require only minimal alteration.

During mass spectral acquisition, it is likely that many projects will require the analysis of compound groups other than small molecules. The IMS parameters for acquisition and the selection of matrix, therefore, should be adapted to generate the best data for the respective target, if it is known. Additionally, we only have performed data acquisition in positive mode with a 50:50 CHCA:DHB matrix, but negative mode experiments may prefer a different type of matrix, and larger molecules would be more easily detected in a different matrix as well. The method can be used with a wide mass range in an untargeted approach or with a narrower mass range for a targeted search. In the case of the above discussed method, small molecules were the target of interest because the focus was to detect molecules that were exchanged through the agarose between cell and tissue representatives. Although we cannot claim the limitations in terms of size and structure that inhibit movement through agarose, our aim was to detect small molecules, so our matrix decision and MALDI-TOF MS parameters were optimized for that goal. Future experiments are being developed to target lipids and proteins that may have been missed in our original acquisition method.

In addition to the limitation of compound class detection, this method also requires that the cells be compatible with agarose, and that the tissue sample (if used) be adapted to fit into an eight-well chamber. Certain tissues can be adapted to larger wells if fewer biological conditions are required for comparison, but it is crucial that the selected tissue is capable of drying to a uniform height of less than 100 to 200 microns after desiccation<sup>4</sup>. Multiple biological samples could be evaluated such as more than one cell type in communication with a tissue. Because the sample

preparation is able to spatially separate agarose-based cell cultures, it is possible to assign visualized m/zs to the cell culture source based on observed diffusion patterns.

Using IMS to study tissue sections from human samples or transgenic mouse models recapitulates the complexity of tissues. However, human samples are difficult to obtain, which can dramatically limit the ability to study things like disease progression. Tissue from transgenic mouse models can be collected at well-defined time points. But, mouse models can be time consuming and expensive to develop. In addition, the full complexity of real tissues in both of these models can make it difficult to accurately evaluate communication between specific cells or tissues. In contrast, the method presented here is a highly adaptable. Different tissues or cell lines can be cocultured on the same slide to examine differences in communication. For example, normal cells or tumor cells from the same tissue can be cultured on the same slide to understand differences due to transformation. Time course studies may uncover novel signaling cascades between cells, or small molecule inhibitors and/or RNAi could be incorporated to examine the role of specific signaling molecules or metabolites. We believe these possibilities will make this technique useful for studying cell-to-cell communication in a wide variety of contexts.

#### **ACKNOWLEDGMENTS:**

Funding was provided by the Chicago Biomedical Consortium with support from the Searle Funds at The Chicago Community Trust (C-076) (L.M.S.); University of Illinois at Chicago Startup Funds (L.M.S.); Grant 543296 from the Ovarian Cancer Research Fund Alliance (M.D.); and UG3 ES029073 (J.E.B.).

#### **DISCLOSURES:**

The authors have nothing to disclose

#### **REFERENCES:**

- (1) Paine, M. R. et al. Whole Reproductive System Non-Negative Matrix Factorization Mass Spectrometry Imaging of an Early-Stage Ovarian Cancer Mouse Model. *PLoS One* **11** (5), e0154837 (2016).
- (2) Yang, Y.-L., Xu, Y., Straight, P., Dorrestein, P. C. Translating Metabolic Exchange with Imaging
   Mass Spectrometry. *Nature Chemical Biology*. 5 (12), 885–887.
   https://doi.org/10.1038/nchembio.252 (2009).
  - (3) Li, H., Hummon, A. B. Imaging Mass Spectrometry of Three-Dimensional Cell Culture Systems. *Analytical Chemistry.* **83** (22), 8794–8801. https://doi.org/10.1021/ac202356g (2011).
  - (4) Yang, J. Y. et al. Primer on Agar-Based Microbial Imaging Mass Spectrometry. *Journal of Bacteriology.* **194** (22), 6023–6028. https://doi.org/10.1128/JB.00823-12 (2012).
  - (5) Coscia, F. et al. Integrative Proteomic Profiling of Ovarian Cancer Cell Lines Reveals Precursor Cell Associated Proteins and Functional Status. *Nature Communications*. **7**, 12645. https://doi.org/10.1038/ncomms12645 (2016).
- 482 (6) Labidi-Galy, S. I. et al. High Grade Serous Ovarian Carcinomas Originate in the Fallopian 483 Tube. *Nature Communications*. **8** (1). https://doi.org/10.1038/s41467-017-00962-1 484 (2018).

- (7) Klinkebiel, D., Zhang, W., Akers, S. N., Odunsi, K., Karpf, A. R. DNA Methylome Analyses
   Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.
   Molecular Cancer Research. 14 (9), 787–794. https://doi.org/10.1158/1541-7786.MCR-16-0097 (2016).
- 489 (8) Falconer, H., Yin, L., Gronberg, H., Altman, D. Ovarian Cancer Risk After Salpingectomy: A
  490 Nationwide Population-Based Study. *JNCI Journal of the National Cancer Institute*. **107**491 (2), dju410–dju410. https://doi.org/10.1093/jnci/dju410 (2015).
- 492 (9) Dean, M., Davis, D. A., Burdette, J. E. Activin A Stimulates Migration of the Fallopian Tube 493 Epithelium, an Origin of High-Grade Serous Ovarian Cancer, through Non-Canonical 494 Signaling. *Cancer Letters.* **391**, 114–124, https://doi.org/10.1016/j.canlet.2017.01.011 495 (2017).
- 496 (10) King, S. M., Burdette, J. E. Evaluating the Progenitor Cells of Ovarian Cancer: Analysis of Current Animal Models. *BMB Reports.* **44** (7), 435 (2011).

500

501

502

503


504


505

506

507

- 498 (11) Reznik, E. et al. Landscape of Metabolic Variation across Tumor Types. *Cell Systems.* **6** (3), 499 301-313.e3. https://doi.org/10.1016/j.cels.2017.12.014 (2018).
  - (12) Watkins, J. L. et al. Clinical Impact of Selective and Nonselective Beta-Blockers on Survival in Patients with Ovarian Cancer: Beta-Blockers and Ovarian Cancer Survival. *Cancer.* **121** (19), 3444–3451. https://doi.org/10.1002/cncr.29392 (2015).
  - (13) Lutgendorf, S. K. et al. Stress-Related Mediators Stimulate Vascular Endothelial Growth Factor Secretion by Two Ovarian Cancer Cell Lines. *Clinical Cancer Research.* **9** (12), 4514–4521 (2003).
  - (14) Sood, A. K. Stress Hormone-Mediated Invasion of Ovarian Cancer Cells. *Clinical Cancer Research.* **12** (2), 369–375. https://doi.org/10.1158/1078-0432.CCR-05-1698 (2006).
- (15) Hoffmann, T., Dorrestein, P. C. Homogeneous Matrix Deposition on Dried Agar for MALDI
   Imaging Mass Spectrometry of Microbial Cultures. *Journal of The American Society for* Mass Spectrometry. 26 (11), 1959–1962. https://doi.org/10.1007/s13361-015-1241–
   1248 (2015).
- (16) Zink, K. E., Dean, M., Burdette, J. E., Sanchez, L. M. Imaging Mass Spectrometry Reveals
   Crosstalk between the Fallopian Tube and the Ovary That Drives Primary Metastasis of
   Ovarian Cancer. ACS Central Science. 4 (10), 1360–1370,
   https://doi.org/10.1021/acscentsci.8b00405 (2018).
- (17) Armaiz-Pena, G. N. et al. Src Activation by β-Adrenoreceptors Is a Key Switch for Tumour
   Metastasis. *Nature Communications.* 4, 1403. https://doi.org/10.1038/ncomms2413
   (2013).
- (18) Choi, M. J. et al. HTERT Mediates Norepinephrine-Induced Slug Expression and Ovarian
   Cancer Aggressiveness. *Oncogene*. 34 (26), 3402 (2015).







# a) Dried slide with no wrinkles in agarose



b) Dried slide with wrinkles in agarose



# a) Well positioned (centered) tissue for IMS analysis




b) Poorly positioned tissue for IMS analysis







a) Dried slide with regions of interest (ROIs) selected for IMS analysis



b) Filter for m/z 184 after IMS acquisition





Name of Material/ Equipment	Company	<b>Catalog Number</b>
15 mL Falcon tubes 8-well chamber (Millipore EZ-slide	Denville	C1017-O
chamber)	Millipore	PEZGS0816
Acetonitrile	Sigma-Aldrich	34998-4L
Alpha Minimum Essential Medium	_	
(αMEM)	Fisher	10-022-CV
Autoflex speed MALDI-TOF LRF	Bruker	
Centrifuge	Eppendorf	5810 R
CHCA Matrix	Bruker Daltonic	8201344
DHB Matrix	Bruker Daltonic	8201346
Disposable Scalpels	Fisher	22-079-707
Dissecting Scissors	Fisher	13-804-6
DMEM Media	Gibco	11995-065
epidermal growth factor	Peprotech Inc.	100-15
Eppendorf tubes	Genesee Scientific	22-282
Estradiol-17β	Simga-Aldrich	E2758
Fetal Bovine Serum	Denville	fb5001
FlexControl 3.4	Bruker Daltonic	
FlexImaging 4.1	Bruker Daltonic	
Forceps (fine)	Fsiher	22-327379
Gentamycin	Cellgro	30-005-CR
Insulin, Transferrin, Selenium (ITS)	Sigma-Aldrich	11074547001
ITO-coated slide	Bruker	8237001
Leibovitz's L-15 Medium	Gibco	11415064
L-glutamine	Gibco	25030-081
Low-melting agarose	Sigma-Aldrich	A9414-10G
Media basin	Corning	4870
Penicillin-streptomycin	Gibco	15140-122
Peptide Calibration Standard	Bruker Daltonic	8206195
Phophorus red	Sigma-Aldrich	343-242-5G
SCiLS Lab 2015	Bruker Daltonic	

Surgical Forceps (blunt) TFA TM Sprayer Fisher Fisher Technologies HTX Technologies 08-875-8B A116-50

#### **Comments/Description**

#### To collect cells

Repurposed from Millipore Millicell EZ-slide chamber slide Solvent for sprayed matrix

Cell culture media

For IMS data analysis

To collect cells and remove supernatant

Matrix sprayed onto dried slide

Matrix sprayed onto dried slide

For removal of the ovaries

For removal of the ovaries

Media mixed with agarose

Cell culture media supplement

For agarose aliquots

Cell culture media supplement

Cell culture media supplement

IMS data acquisition software

IMS data analysis software

For removal of the ovaries

Cell culture media supplement

Cell culture media supplement

Platform for co-culture incubation

Media used during tissue dissection

Cell culture media supplement

Mixed with media for plating

Used to cut plastic dividers for divided chambers

Cell culture media supplement

Calibrant for medium mass range

Calibrant for low mass range

IMS data statistical analysis

For removal of the ovaries Added to matrix solution For applying matrix



#### ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	using imaging mass spectrometry
Author(s):	Katherine E Zink, Matthew Dean, Joanna E Burdette, Laura M Sanchez
Item 1 (check one	box): The Author elects to have the Materials be made available (as described a
http://www.j	ove.com/author) via: X Standard Access Open Access
Item 2 (check one bo	x):
X The Auth	or is NOT a United States government employee.
	hor is a United States government employee and the Materials were prepared in the or her duties as a United States government employee.
	or is a United States government employee but the Materials were NOT prepared in the or her duties as a United States government employee.

A newly developed method for capturing small molecule communication between tissues and cells

#### ARTICLE AND VIDEO LICENSE AGREEMENT

- 1. Defined Terms. As used in this Article and Video License Agreement, the following terms shall have the following meanings: "Agreement" means this Article and Video License Agreement; "Article" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "Author" means the author who is a signatory to this Agreement; "Collective Work" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "CRC License" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found http://creativecommons.org/licenses/by-ncnd/3.0/legalcode; "Derivative Work" means a work based upon the Materials or upon the Materials and other preexisting works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "Institution" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "JoVE" means MyJove Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; "Materials" means the Article and / or the Video; "Parties" means the Author and JoVE; "Video" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.
- 2. <u>Background</u>. The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.
- 3. Grant of Rights in Article. In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.



#### ARTICLE AND VIDEO LICENSE AGREEMENT

- 4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.
- 5. <u>Grant of Rights in Video Standard Access</u>. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.
- 6. Grant of Rights in Video Open Access. This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.
- 7. <u>Government Employees.</u> If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

- statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.
- 8. <u>Likeness, Privacy, Personality</u>. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.
- 9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.
- 10. <u>JoVE Discretion</u>. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have



#### ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. Indemnification. The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

- 12. <u>Fees</u>. To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.
- 13. <u>Transfer, Governing Law</u>. This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

#### **CORRESPONDING AUTHOR:**

Name:	Laura Sanchez				
Department:	Medicinal Chemistry and Pharmacognosy				
Institution:	University of Illinois at Chicago				
	A newly developed method for capturing small molecule communication between tissues and cells using				
Article Title:	imaging mass spectrometry.				
Signature:	Janus Date:	12/4/18			

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pfd on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For guestions, please email submissions@jove.com or call +1.617.945.9051

#### **Editorial comments:**

**1.** Title: Please shorten the title if possible. For instance, "A newly developed method for" may be deleted.

We have now shortened the title as suggested.

**2.** Please rephrase the Introduction to include a clear statement of the overall goal of this method.

We have added the following statement to the introduction "The overall goal of this method is to elucidate the identity and spatial distribution of small molecules during exchange between tissues and organs, represented either by in vitro 3D cell cultures or ex vivo tissue"

**3.** Please place the ethics statement before your numbered protocol steps, indicating that the protocol follows the animal care guidelines of your institution.

We have added the following statement "All animal procedures were in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and approved by the Institutional Animal Use and Care (IACUC) committee at the University of Illinois at Chicago."

**4.** Please revise the protocol to contain only action items that direct the reader to do something (e.g., "Do this," "Ensure that," etc.). The actions should be described in the imperative tense in complete sentences wherever possible. Avoid usage of phrases such as "could be," "should be," and "would be" throughout the Protocol. Any text that cannot be written in the imperative tense may be added as a "Note." Please include all safety procedures and use of hoods, etc. However, notes should be used sparingly and actions should be described in the imperative tense wherever possible. Please move the discussion about the protocol to the Discussion.

#### This was done throughout.

- **5.** Please add more details to your protocol steps. There should be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol. Please ensure you answer the "how" question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action. See examples below.
- **6. 1.1:** Please provide some guidance on how often to pass the cells.

We have added the following "Pass the cells every 3-4 day, ensuring there are enough cells on the same day the mice will be sacrificed."

**7**. 2.3: Is the mouse anesthetized before the procedure? Please mention how animals are anesthetized and how proper anesthetization is confirmed. Please specify all surgical tools used.

The process of euthanasia and the removal of the ovary has been explain in much more detail. Please see sections 2.1-2.7.

**8.** Figure 5: Please describe the top and bottom panels in the figure legend.

The following has been added "Top: Slide after 2 h desiccation with 8-well chamber adhered. All agarose plugs but two cracked through the center due to adhesion to the 8-well chamber. Bottom: Slide after removal of 8-well chamber. Only one agarose plug remained on the slide."

#### Reviewer 1

It's not clear in the manuscript the impact the desiccation process may have on cellular metabolism. It would be useful to consider if a quenching step would enable a more accurate determination of cellular signaling. The current process may suffer from an artefactual response to desiccation. It may be worth considering an alternative approach to desiccation at 37 degrees Celsius. Perhaps quenching with liquid nitrogen and/or approaching the process using a freezedry method might more accurately preserve the cellular signaling environment.

In the context of initially optimizing the protocol, the desiccation is necessary to adhere the agarose to the ITO slides, from previous experience with agar based imaging, freeze-dry actually causes the agar/agarose to swell which distorts the cells and frequently causes bubbles to appear. While we have not tried liquid nitrogen it is anticipated that this would cause the agarose to become too brittle which would not allow it to adhere to the ITO slides. Desiccation at 37 is therefore optimal. We have also screened in developing the protocol for artifacts and cell lysis with peroxide followed by desiccation causes different signals to appear which leads us to believe that we are capturing the signaling chemistry to the best of our ability and not simply cell death via desiccation.

#### **Reviewer 2**

1. For full accuracy, "MALDI-TOF" should be referred throughout as "MALDI-TOF MS" (matrix-assisted laser desorption/ionization time-of-flight mass spectrometry).

Thank you for catching this oversight on our part, this has been corrected throughout.

2. Protocol section: numerous acronyms are not defined (MOE, FBS, MEM, DMEM, ITO, CHCA, DHB...)

These have been added throughout.

3. Line 218: Distance value is missing.

Thank you for catching this oversight on our part, this has been corrected.

4. Line 220: "aTM" should read "a TM".

Thank you for catching this oversight on our part, this has been corrected.

5. Although specified in the Table of Materials, please specify in the methods the manufacturer and model of the MALDI-TOF mass spectrometer used.

JoVE cannot publish manuscripts containing commercial language, which limits the manufacturer and model to the Table of Materials.

6. Lines 247-248: "Reflector gain = 3x" makes no sense and should probably read "Reflectron mode detector gain = 3x".

Thank you for catching this oversight on our part, this has been corrected.

7. The symbol for "hours" is "h" and not "hrs". Please correct where necessary.

Thank you for catching this oversight on our part, this has been corrected.

8. I would add a dimension scale to Figure 1. There is one in Figure 6 but it comes too late in the manuscript.

Thank you for catching this oversight on our part, this has been corrected.

9. Identity of m/z 184 and 112 in Figures 6 and 7, respectively would have been welcomed.

We are in the process of identifying more signals, but new results are outside the scope of this protocol as both chemical and biological validation of the signals is necessary.



Laura Sanchez <sanchelm@uic.edu>

### Fwd: Regarding Incident 2417675 Request for image reuse

Katherine Zink <kzink2@uic.edu> To: sanchelm@uic.edu

Fri, Dec 7, 2018 at 3:05 PM

Granted!

Begin forwarded message:

From: support@services.acs.org

Date: December 7, 2018 at 3:51:44 PM EST

To: kzink2@uic.edu

Subject: Regarding Incident 2417675 Request for image reuse



Dear Katherine Zink,

Thank you for contacting ACS Publications Help Desk.

Your permission requested is granted and there is no fee for this reuse. In your planned reuse, you must cite the ACS article as the source, https://pubs.acs.org/doi/abs/10.1021%2Facscentsci.8b00405, and further permissions related to the material excerpted should be directed to the ACS.

Should you have any questions or need further assistance, please feel free to contact me.

Sincerely,

Deleep Kumar

**ACS Customer Services & Information** 

Incident Information:

Incident #: 2417675

2018-12-06T14:21:28 Date Created:

3 Priority:

Katherine Zink Customer:

Title: Request for image reuse

Description: Hello,

I am writing to request the reuse of several SI images from Imaging Mass Spectrometry Reveals Crosstalk between the Fallopian Tube and the Ovary that Drives Primary Metastasis of Ovarian Cancer.

I am requesting to reuse images from the following Supporting Information Figures:

- 1. Figure S2
- 2. Figure S4
- 3. Figure S6
- 4. Figure S15

The content will be modified and reused in an invited article in the Journal of Visualized Experiments.

Thank you very much for your consideration.

Katherine E Zink

PhD Candidate

Pharmacognosy

University of Illinois at Chicago

{CMI: MCID582833}